Equity Field Notes from temporal sources

[DanWebzster]

APTO (update)

You have to be good at not chasing to remain a trader. This means living with the feeling of missing out, often.

This stock moves on gurus' ( who I respect) assessment of promise, despite being early stage and relatively under-capitalized.

One thing I learned from Clover Bio is that some of the APTO optimism revolves around the fact that blood cancer drugs have historically better odds of success.

APTO raised $20mn from a stock purchase agreement with Aspire Capital on 5/31/18. This is about 10% of the capital they would need to become viable commercially viable.